Opinion|Videos|January 22, 2025
Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia
Panelists discuss the data updates from the AUGMENT-101 trial, the potential of revumenib to reshape the treatment landscape for patients with heavily pretreated KMT2A-rearranged acute leukemia, including its observed objective response rate (ORR) and complete remission (CR)/ CR with partial recovery of peripheral blood counts (CRh) rate, and the clinical implications of revumenib in the context of bridging to stem cell transplantation.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on data updates presented for the AUGMENT-101 trial.
- Given the 64% ORR and 23% CR/CRh rate observed with revumenib in patients with heavily preated pretreated KMT2A-rearranged acute leukemia patients, how do you see this therapy reshaping the treatment landscape for this high-risk population?
- Briefly comment on the clinical implications, particularly in the context of bridging to stem cell transplantation.?
Advertisement
Related to this article
Many patients with IDH-mutant glioma continued to receive vorasidenib as directed in the real-world GLIO-ADHERE claims analysis.
Mirdametinib produced stable disease or partial responses in adults and children with plexiform neurofibromas who had received another MEK inhibitor.
Longer follow-up of the phase 3 INDIGO trial showed that vorasidenib lowered seizure rates in IDH-mutant glioma, an effect driven by oligodendroglioma.
Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Advertisement
Advertisement
Trending on OncLive
1
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
4
Patient Preferences Steer Decisions as Options Multiply Across EGFR-Mutated NSCLC
5